Evidence map›Paper›PMID 29722656›Full record

ArticleInternational journal of radiation oncology, biology, physics2018

Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031.

Aaron Parzuchowski, Rizvan Bush, Qinglin Pei, Debra L Friedman, Thomas J FitzGerald, Suzanne L Wolden, Kavita V Dharmarajan, Louis S Constine, Fran Laurie, Sandy K Kessel and 6 more

Open access · greenAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Quality assurance in radiation oncology.Pediatric blood & cancer · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 2 countries.

Aaron ParzuchowskiDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Rizvan BushChildren's Oncology Group, Monrovia, California.
Qinglin PeiChildren's Oncology Group, University of Florida, Gainesville, Florida.
Debra L FriedmanDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Thomas J FitzGeraldDepartment of Radiation Oncology, University of Massachusetts Medical Center, Worcester, Massachusetts.
Suzanne L WoldenDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Kavita V DharmarajanDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Louis S ConstineDepartment of Radiation Oncology, University of Rochester, Rochester, New York.
Fran LaurieQuality Assurance Review Center, Lincoln, Rhode Island.
Sandy K KesselQuality Assurance Review Center, Lincoln, Rhode Island.
Burton AppelHackensack University Medical Center, Hackensack, New Jersey.
Karen FernandezDepartment of Oncology, University of Illinois College of Medicine at Peoria, Peoria, Illinois.
Angela PunnettDepartment of Paediatrics, University of Toronto, Toronto, Ontario, Canada.
Cindy L SchwartzDepartment of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, Texas.
Jacob CoxDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Stephanie A TerezakisDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: stereza1@jhmi.edu.
Johns Hopkins Medicine · USChildren's Oncology Group · USHackensack University Medical Center · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Florida · USUniversity of Illinois Chicago · USUniversity of Massachusetts Chan Medical School · USUniversity of Rochester · USUniversity of Toronto · CAVanderbilt University · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

purposeThe presented protocol for pediatric intermediate-risk Hodgkin lymphoma evaluated the use of a dose-intensive chemotherapy regimen (ABVE-PC [doxorubicin, bleomycin, vincristine, etoposide, cyclophosphamide, prednisone]) with response-based therapy augmentation (addition of DECA [dexamethasone, etoposide, cisplatin, cytarabine]) or therapy reduction (elimination of radiation). METHODS AND MATERIALS: A central review of the radiation therapy data for quality assurance was performed, and the association between radiation protocol deviation (RPD) and relapse was assessed in the pediatric group (age <15 years) and adolescent and young adult (AYA) group (age ≥15-21 years). Involved-field radiation therapy (IFRT) planning was reviewed before the start of treatment and at treatment completion. The records were reviewed through the Quality Assurance Review Center's central review to identify RPD, classified according to dose deviation (DD), volume deviation (VD), undertreatment (UT), and overtreatment (OT). DDs and VDs were further classified as major or minor.

resultsOf the 1712 patients enrolled, 1155 received IFRT, of whom, 216 (18.7%) had RPDs. The DD and VD patterns were similar between the pediatric and AYA groups. Minor VDs were most common. UT RPDs accounted for 69% in the pediatric group and 75% in the AYA group. Of the 35 patients with relapse and a RPD, 29 had an undertreatment RPD. Among the patients who received IFRT, a significant difference was found in the cumulative incidence rates of relapse between the pediatric and AYA groups (P = .03); however, no significant difference was found between patients with and without RPD (P = .2).

conclusionsMost RPDs were minor and consisted of UT in the AYA and pediatric populations both. No difference was observed in RPDs between the pediatric and AYA patients. Thus, in a well-defined and standardized protocol, the RPD distributions for AYA patients will be similar to those for pediatric population. However, the increased cumulative incidence of relapse in the AYA patients who had received IFRT compared with the pediatric population requires further exploration, given the potential differences in clinical outcomes in the AYA population.

Indexed as

AdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFemaleHodgkin DiseaseHumansInfantInfant, NewbornBleomycinCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposidePrednisoneVincristine

Identifiers

PMID29722656
PMCPMC6555555
OpenAlexW2781674579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.